Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...

Verzenio is a CDK4/CDK6 inhibitor which helps slow down the growth of cancer in women with HR-positive, HER-2 negative metastatic breast cancer. And now women with early-stage disease, regardless of ...

All of these are medications in Lilly's weight loss portfolio. However, another star performer throughout 2024 was Verzenio -- Lilly's main oncology treatment. For the nine months ended Sept.

During a clinical trial, researchers found that CDK4/CDK6 inhibitor Verzenio may have a huge impact on women battling early stage breast cancer by decreasing the likelihood of the cancer returning.

Verzenio’s label expanded to include the full study population investigated in the Verzenio Phase 3 monarchE trial. Approval supported by four-year data from the monarchE trial; Verzenio added to ...